New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > SAR STS - IFOSFamide and DOXOrubicin [ARST0332] [intermediate and high risk] > SAR - IFOSFamide ARST0332 [intermediate and high risk]
This regimen is a component of SAR STS - IFOSFamide and DOXOrubicin [ARST0332] [intermediate and high risk]

ARST0332 [intermediate and high risk] - I [IFOSFamide] (SAR STS - IFOSFamide and DOXOrubicin [ARST0332] [intermediate and high risk])

Treatment Overview

As cycles 3 and 4 (refer Treatment Schema), or as per patient's individual treatment plan.


This regimen contains a medicine where one or more biosimilars may exist. Any biosimilars used have been reviewed by the regulator (Medsafe) and relevant specialists were consulted nationally. Where regulators, in consultation with relevant specialists, have agreed that there are no clinically significant differences in either safety or effectiveness between a biosimilar and originator product, these drugs may be used interchangeably.

Cycles 1 to 2 - 21 days

Cycle length:
21

mesna: Dosing as per ARST0332 protocol.

Cycle details

Cycles 1 to 2 - 21 days

Medication Dose Route Days Max Duration
olanzapine * 5 mg oral administration 1 to 6
aprepitant 125 mg oral administration 1
aprepitant 80 mg oral administration 2, 3
dexamethasone * 12 mg oral administration 1
dexamethasone * 8 mg oral administration 2 to 6
ondansetron 8 mg oral administration 1, 2, 3
sodium chloride 0.9 % intravenous 1, 2, 3 120 minutes
mesna 600 mg/m² intravenous 1, 2, 3 15 minutes
IFOSFamide * 3000 mg/m² Once daily intravenous 1, 2, 3 3 hours
sodium chloride 0.9 % intravenous 1, 2, 3 120 minutes
mesna 600 mg/m² intravenous 1, 2, 3 15 minutes
mesna 600 mg/m² intravenous 1, 2, 3 15 minutes
mesna 600 mg/m² intravenous 1, 2, 3 15 minutes
ondansetron 8 mg oral administration 1, 2, 3
pegFILGRASTIM 6 mg subcutaneous injection 4
cyclIZINE 50 mg Three times daily oral administration 1

mesna: Dosing as per ARST0332 protocol.

Full details

Cycles 1 to 2 - 21 days

Day: 1

Medication Dose Route Max duration Details
olanzapine * 5 mg oral administration
Instructions:

ONE hour prior to chemotherapy.

  • This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
  • Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment.
aprepitant 125 mg oral administration
Instructions:
ONE hour prior to chemotherapy.
dexamethasone * 12 mg oral administration
Instructions:

ONE hour prior to chemotherapy with food.
ondansetron 8 mg oral administration
Instructions:

ONE hour prior to chemotherapy.
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

Prior to IFOSFamide infusion.

Recommended daily hydration is 3000 ml per day as oral or IV fluid on day(s) of IFOSFamide and for 24 hours after, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

Immediately prior to IFOSFamide over 15 minutes, or as per institutional practice.
IFOSFamide * 3000 mg/m² Once daily intravenous 3 hours
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

After IFOSFamide infusion.

Recommended daily hydration is 3000 ml per day as oral or IV fluid on day(s) of IFOSFamide and for 24 hours after, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 3 hours after the start of the IFOSFamide infusion, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 6 hours after the start of the IFOSFamide infusion, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 9 hours after the start of the IFOSFamide infusion, or as per institutional practice.
ondansetron 8 mg oral administration
Instructions:

EIGHT hours after chemotherapy OR before bed.
cyclIZINE 50 mg Three times daily oral administration
Instructions:

When required for nausea and/or vomiting.

  • Warning: may cause drowsiness.
  • Consider starting dose at 25 mg and increasing as tolerated/required.
  • The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.
  • Note that domperidone is not recommended in combination with olanzapine and ondansetron due to potential risk of QT prolongation.

Day: 2

Medication Dose Route Max duration Details
olanzapine * 5 mg oral administration
Instructions:

ONCE daily.

This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
aprepitant 80 mg oral administration
Instructions:
ONCE daily in the morning.
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.
ondansetron 8 mg oral administration
Instructions:

ONE hour prior to chemotherapy.
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

Prior to IFOSFamide infusion.

Recommended daily hydration is 3000 ml per day as oral or IV fluid on day(s) of IFOSFamide and for 24 hours after, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

Immediately prior to IFOSFamide over 15 minutes, or as per institutional practice.
IFOSFamide * 3000 mg/m² Once daily intravenous 3 hours
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

After IFOSFamide infusion.

Recommended daily hydration is 3000 ml per day as oral or IV fluid on day(s) of IFOSFamide and for 24 hours after, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 3 hours after the start of the IFOSFamide infusion, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 6 hours after the start of the IFOSFamide infusion, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 9 hours after the start of the IFOSFamide infusion, or as per institutional practice.
ondansetron 8 mg oral administration
Instructions:

EIGHT hours after chemotherapy OR before bed.

Day: 3

Medication Dose Route Max duration Details
olanzapine * 5 mg oral administration
Instructions:

ONCE daily.

This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
aprepitant 80 mg oral administration
Instructions:
ONCE daily in the morning.
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.
ondansetron 8 mg oral administration
Instructions:

ONE hour prior to chemotherapy.
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

Prior to IFOSFamide infusion.

Recommended daily hydration is 3000 ml per day as oral or IV fluid on day(s) of IFOSFamide and for 24 hours after, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

Immediately prior to IFOSFamide over 15 minutes, or as per institutional practice.
IFOSFamide * 3000 mg/m² Once daily intravenous 3 hours
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

After IFOSFamide infusion.

Recommended daily hydration is 3000 ml per day as oral or IV fluid on day(s) of IFOSFamide and for 24 hours after, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 3 hours after the start of the IFOSFamide infusion, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 6 hours after the start of the IFOSFamide infusion, or as per institutional practice.
mesna 600 mg/m² intravenous 15 minutes
Instructions:

At 9 hours after the start of the IFOSFamide infusion, or as per institutional practice.
ondansetron 8 mg oral administration
Instructions:

EIGHT hours after chemotherapy OR before bed.

Day: 4

Medication Dose Route Max duration Details
olanzapine * 5 mg oral administration
Instructions:

ONCE daily.

This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.
pegFILGRASTIM 6 mg subcutaneous injection

Day: 5

Medication Dose Route Max duration Details
olanzapine * 5 mg oral administration
Instructions:

ONCE daily.

This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.

Day: 6

Medication Dose Route Max duration Details
olanzapine * 5 mg oral administration
Instructions:

ONCE daily.

This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
dexamethasone * 8 mg oral administration
Instructions:

ONCE daily in the morning with food.

Dose and duration may be individualised at clinician’s discretion.

Supportive Care Factors

Factor Value
Emetogenicity: High
Growth factor support: Recommended for primary prophylaxis
Hydration: Routine hydration recommended
Mesna uroprotection: Routine mesna uroprotection recommended

References

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142., PMID: 28848668

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14., PMID: 29443651

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.